NCAM1 and thyroiditis: Meanwhile, another study has found that patients with pembrolizumab-induced thyroiditis had elevated circulating CD56+CD16+ natural killer cells, without elevation of the CD3+ T-cell count, or the CD4+ and CD8+ T-cell sub-populations.